Evaluation of 626 in Healthy Adult Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions

Healthy Subjects (HS)

Interventions

DRUG

626

Single subcutaneous injection

DRUG

Placebo

Single subcutaneous injection

Trial Locations (1)

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY